Skyhawk Therapeutics Taps Neurology Commercial Veteran to Lead Huntington's Drug Launch — Skyhawk Therapeutics, Inc.

Event summary

Skyhawk Therapeutics appoints Aaron Deves as Chief Commercial Officer to lead commercialization of SKY-0515 for Huntington's disease.
Deves brings 30 years of experience in commercializing neurological therapies, including AUSTEDO® for Huntington's disease chorea.
Skyhawk may receive accelerated approval for SKY-0515 in Australia within the next 12 months, with potential launches in other major markets in 2027.
Deves previously led commercial teams at Teva Pharmaceuticals, Otsuka Pharmaceuticals, and Pfizer.

The big picture

Skyhawk's appointment of Deves underscores its strategic focus on commercializing SKY-0515 as a potential disease-modifying therapy for Huntington's disease. The move comes as the company prepares for potential regulatory approvals and market launches, positioning itself in a competitive landscape for neurological treatments. Deves' extensive experience in commercializing neurological therapies adds significant operational expertise to Skyhawk's leadership team.

What we're watching

Regulatory Timing: Whether Skyhawk can secure accelerated approval for SKY-0515 in Australia within the next 12 months and meet 2027 launch targets in other major markets.
Commercial Execution: How effectively Deves can build and lead a commercial team to launch SKY-0515, given his extensive experience in the neurological space.
Pipeline Potential: The pace at which Skyhawk can advance its pre-clinical pipeline of RNA-targeting drug programs for other challenging neurological conditions.